Clinical Data from Two Phase II Studies Evaluating REVLIMID® Plus Rituximab in Indolent Non-Hodgkin's Lymphomas ...
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two investigational studies evaluating the combination of REVLIMID® (lenalidomide) plus rituximab in indolent non-Hodgkin's lymphoma (NHL) were presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL. In the first study, treatment with ...
Read more on Business Wire
Orignal From: Clinical Data from Two Phase II Studies Evaluating REVLIMID® Plus Rituximab in Indolent Non-Hodgkin's Lymphomas ...
Post a Comment